Table of Contents
- Overview
- Symptoms
- Treatment
- Prevention
- Images
Acute myelogenous leukemia; AML; Acute granulocytic leukemia; Acute nonlymphocytic leukemia (ANLL); Leukemia - acute myeloid (AML); Leukemia - acute granulocytic; Leukemia - nonlymphocytic (ANLL)
Treatment
Treatment involves using medicines to kill the cancer cells. This is called
Other treatments for AML may include:
- Antibiotics to treat infection
-
Bone marrow transplant or stem cell transplant after radiation and chemotherapy - Red blood cell transfusions to fight anemia
- Transfusions of
platelets to control bleeding
Most types of AML are treated the same way. However, a form of AML called acute promyelocytic leukemia (APL) is treated with a medicine called all-trans retinoic acid (ATRA). This medicine helps leukemia cells grow into normal white blood cells.
The drug arsenic trioxide is for use in patients with APL who do not get better with ATRA or chemotherapy.
Support Groups
See:
Cancer support group Leukemia support group
Expectations (prognosis)
When the signs and symptoms of AML go away, you are said to be in remission. Complete remission occurs in most patients.
With treatment, younger patients with AML tend to do better than those who develop the disease at an older age. The 5-year survival rate is much lower in older adults than younger persons. Experts say this is partly due to the fact that the body of a younger person can better tolerate strong chemotherapy medicines.
If the cancer does not come back (relapse) within 5 years of the diagnosis, you are considered permanently cured.
Complications
Complications of AML and cancer treatment include severe infections and life-threatening bleeding. Sometimes, the cancer comes back (relapses) after treatment.
Calling your health care provider
Call for an appointment with your health care provider if you develop symptoms of AML.
Call your health care provider if you have AML and have a fever that will not go away or other signs of infection.
Previous Section
Review Date: 09/06/2010
Reviewed By: David C. Dugdale, III, MD, Professor of Medicine, Division of
General Medicine, Department of Medicine, University of Washington
School of Medicine; James R. Mason, MD, Oncologist, Director, Blood
and Marrow Transplantation Program and Stem Cell Processing Lab,
Scripps Clinic, Torrey Pines, California. Also reviewed by David
Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org)
